


Hidden Gems Webinar, May 19, 2023
“Addressing the Leading Causes of Blindness”
Nova Eye Medical Limited (ASX:EYE)

DISCLAIMER



This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. This presentation may contain forward looking statements. These forward-looking statements have been made based upon Nova Eye Medical's expectations and beliefs concerning future developments and their potential effect on Nova Eye Medical (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Nova Eye Medical's control. No assurance is given that future developments will be in accordance with Nova Eye Medical's expectations. Actual results could differ materially from those expected by Nova Eye Medical. This presentation does not constitute an offer to sell or a solicitation or an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective. The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. It is also not intended to inform or guide clinical decisions.



BUSINESS SNAPSHOT



Nova Eye Medical leads the way in interventional treatment solutions for glaucoma and age-related macular degeneration (AMD), **the leading causes of blindness in the developed world.**

Nova Eye Medical, Glaucoma	
Strategy	Develop, market and sell comprehensive portfolio of glaucoma consumable surgical devices
Market	Canaloplasty segment of the glaucoma surgical devices market scheduled to grow rapidly 2022-27
Sales	Established infrastructure; direct sales in USA, Germany, Australia; +20 distributors
Manufacturing	California, USA and Dunedin, New Zealand
IP Status	>100 patents issued and pending
Regulatory	Clearance in all key global markets, including USA (FDA)
Reimbursement	Favorable CPT codes (USA)

AlphaRET, AMD	
Strategy	Progress 2RT® to market-ready status with partner for confirmatory study
Market	Intermediate Age-related Macular Degeneration treatment (iAMD) – market not addressed
Sales	Sales program to coincide with partnering
Manufacturing	Adelaide, Australia based contract manufacturing
IP Status	First mover advantage, >10 patents issued and pending in major markets
Regulatory	CE Mark (iAMD and diabetic eye disease) in Europe, Australia, NZ
Reimbursement	Pending

COMPANY OVERVIEW

Capital Structure

ASX Code	EYE
Share Price (at 16 May 2023)	\$0.225
Shares on Issue	190 M
Unlisted Options (unquoted securities)	3.35 M
Market Capitalisation	\$42.8 M
Cash (31 December*)	\$11M
Top 20 Shareholders (16 May 2023)	54.90%

Shareholders


Significant shareholder support from the top 20 shareholders (as of 16 May 2023)



■ Top 20 Shareholders

* Proforma Cash at 31 December 2022 adjusted for:
 1) tax refund of \$1.1m received on 6 January 2023.
 2) capital raise 2 March 2023 of \$7.5m

Share Price Chart



■ Volume

OUR GLAUCOMA OPPORTUNITY



- With a proprietary product portfolio and an established glaucoma salesforce, Nova Eye Medical is well positioned to execute its glaucoma opportunity.
- The new **iTrack™ Advance** canaloplasty device, **cleared by the USA Food and Drug Administration (FDA) in early April 2023**, offers significant opportunity for sales growth.
- Capital raise of A\$8 million in March 2023 successfully completed to support commercial roll-out of **iTrack™ Advance**.

Established glaucoma salesforce in the USA – the world’s largest market for ophthalmology.


Paradigm shift towards earlier surgical intervention for glaucoma via MIGS.

High surgeon-demand for glaucoma surgical devices.

GLAUCOMA, DISEASE OVERVIEW



- Glaucoma is the leading cause of blindness in the developed world
- Progressive, irreversible eye disease that causes vision loss due to optic nerve damage.
- Elevated intraocular pressure (IOP) is the most significant risk factor for the development of glaucoma.
- There is no cure for glaucoma.
- Topical medications are standard of care but nonadherence is ubiquitous.



1. Drainage canal becomes blocked; too much fluid stays in the eye and IOP rises.

2. High IOP damages optic nerve.

GLAUCOMA, TREATMENT OVERVIEW

- Traditional treatment paradigm consisted of long-term chronic medication use.
- Patients and surgeons are moving away from medications in favour of minimally invasive glaucoma surgery or MIGS.
- MIGS offer an improved safety profile and are performed earlier in the disease process.
- Advancements in diagnostic technologies also support earlier surgical intervention.
- **Nova Eye is a key player in the global MIGS market with its industry-leading canaloplasty device, iTrack™ Advance.**



Patient adherence to glaucoma medications is poor

10–25% of newly prescribed patients don't refill second prescription


Quigley HA Glaucoma: What Every Patient Should Know 2011; Friedman DS et al Invest Ophthalmol Vis Sci. 2007.

Glaucoma surgical devices are increasingly recognized as a viable alternative to medications – and this is the highest area of focus and return for the patient, the physician and the supplier.

GLAUCOMA, MARKET OVERVIEW




- **The glaucoma consumable surgical devices market is the fastest growing segment of the ophthalmic market.**
- The aging global population drives prevalence, representing a significant opportunity for our global business.
- Significant drawbacks associated with medications drives preferential growth of our proprietary consumable surgical devices.



1. Marketscope 2022 Glaucoma Surgical Devices Reports. Growth in glaucoma surgical devices.

GLAUCOMA, BY GEOGRAPHY




1. Marketscope 2022 Glaucoma Surgical Devices Reports. Growth in glaucoma surgical devices.

iTrack™ Advance



- Our **iTrack™ Advance** MIGS device is redefining the treatment of glaucoma in its early stages.
- Enhanced version of our original iTrack™ microcatheter, which was first brought to market in 2008 and has been used in more than 120,000 procedures globally.
- Offers a stent-free, tissue-preserving surgical treatment for glaucoma.

iTrack™ Advance




iTrack™ Advance



In the USA, iTrack[™] is regularly used by approx. 200 specialist glaucoma surgeons. The new **iTrack[™] Advance** will appeal to the additional 1,100 glaucoma surgeons and the additional 10,000 comprehensive and cataract surgeons.

*"iTrack[™] usage has been primarily by glaucoma specialists. The **iTrack[™] Advance** will make canaloplasty more accessible to the much broader market of cataract and anterior segment surgeons."* David Lubeck, MD (Chicago, USA)



1. Nova Eye estimate

OUR GLAUCOMA OUTLOOK



1

Glaucoma consumable surgical devices represent the fastest growing market in ophthalmology.

2

Best-in-class iTrack™ Advance device approved for sale in the USA, the world's largest market.

3

Established, scalable glaucoma salesforce and commercial infrastructure in USA.

4

Well positioned to support commercial roll-out of iTrack™ Advance following a capital raise in March 2023 for significant sales growth.



NOVAEYE
MEDICAL®